




The relative strengths and weaknesses of Moonlake Immunotherapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Moonlake Immunotherapeutics compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 202% points. The greatest weakness of Moonlake Immunotherapeutics is the variable Other Revenues, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 400%, being 186% points above the market average of 215%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	474,289	Assets	477,933
Cost of Goods Sold	0	Liabilities	24,542
Intangible Assets	0	Expenses	143,373
Liabilities, Current	22,464	Revenues	22,129
Liabilities, Non-Current	2,078	Stockholders Equity	453,391
Other Assets	2,922	Net Income	-121,244
Other Compr. Net Income	4,861	Comprehensive Net Income	-118,814
Other Expenses	282	BaseVar	336,419
Other Liabilities	0	ECR before LimitedLiability	346%
Other Net Income	0	Economic Capital Ratio	400%
Other Revenues	22,129		
Property and Equipment	722		
Research and Development	112,771		
Selling, General and Administrative Expense	30,320		